Official Title: “Efficacy of Losartan in Preventing Progression of COPD”

Evidence in animals shows that losartan can prevent or reverse inflammation and lung damage due to smoking. The goal of this study is to determine whether this drug which is also used to treat hypertension can stabilize or improve lung function in people who have from chronic obstructive pulmonary disease (COPD).

Study Type: Interventional

Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study

Study Primary Completion Date: August 2012

Participants will be given either losartan in a dose of 50-100 mg per day for a period of one year. During that time, they will have lung function tests, breathing tests, and computed tomograms of the chest. These tests will determine whether there is inflammation in the lung and whether there is progressive involvement of the lung with COPD.

Intervention(s) in this Clinical Trial

• Drug: Losartan
  • Losartan 100 mg daily
• Drug: Placebo
  • Placebo pill daily

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: 1
  • Losartan 100 mg daily
• Placebo Comparator: 2
  • Placebo 1 pill daily

Primary Measures

• Extent of emphysema on CT scan
  • Time Frame: Measured at Month 12
    Safety Issue?: No

Secondary Measures

• Pulmonary function testing
  • Time Frame: Measured at Month 12
    Safety Issue?: No

Inclusion Criteria:

• Adults with COPD who are either active or former smokers

Exclusion Criteria:

• Clinical requirement or history of intolerance of angiotensin receptor blockers, serious heart, liver, kidney, neurological disease.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 40 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Overall Clinical Trial Officials and Contacts

Robert A. Wise, MD Principal Investigator Johns Hopkins University  

Overall Contact: Gwen Leatherman, RN 410 550-0800 gleathe@jhmi.edu

Information obtained from ClinicalTrials.gov on November 20, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00720226

Study ID Number: 1 P50 HL084945

ClinicalTrials.gov Identifier: NCT00720226

Health Authority: United States: Federal Government